The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.
A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.
The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback